The most frequent RET fusions have been observed in thyroid cancer (approximately 3% of all cases and 9–11% of the papillary subtype) and in lung adenocarcinoma (approximately 1%) [16,17]. The gene discussed is RET; the disease is lung adenocarcinoma.